首頁 > 市場調查報告書 > 製藥

生技設備生物工藝

北美生物加工市場預測至 2031 年 - 區域分析 - 按產品、營運規模、製程、應用和最終用戶

市場調查報告書

商品編碼

1597070

北美生物加工市場預測至 2031 年 - 區域分析 - 按產品、營運規模、製程、應用和最終用戶

North America Bioprocessing Market Forecast to 2031 - Regional Analysis - by Product, Scale of Operation, Process, Application, and End User

出版日期: 2024年10月03日 | 出版商:

The Insight Partners | 英文 151 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2023年北美生物加工市場價值為124.406億美元，預計到2031年將達到359.5043億美元；預計2023年至2031年複合年成長率為14.2%。

慢性病盛行率的增加推動了北美生物加工市場

老年人久坐的生活增加了肥胖和糖尿病等生活方式障礙的盛行率。遺傳基因也可以表達這些疾病以及其他健康問題，例如心血管疾病（CVD）、阿茲海默症和憂鬱症。據國家老化委員會稱，80% 的成年人（65 歲及以上）一生中至少患有一種慢性病。根據美國疾病管制與預防中心(CDC) 的數據，2020 年，美國大約每10 人中就有6 人患有至少一種嚴重疾病，每10 人中就有4 人患有兩種或兩種以上慢性病。 2015 年至2050 年間，全球60 歲以上人口的比例將幾乎翻倍，從12% 增至22%。有關。因忙碌的生活方式而引起的心絞痛、動脈粥狀硬化和急性心肌梗塞等心血管疾病是全世界死亡的重要原因之一。根據世界心臟基金會的數據，在過去 30 年（1990 年至 2020 年）中，CVD 引起的死亡率激增了 60%。 2021 年，有 2,050 萬人因心血管疾病死亡。糖尿病是危及生命的慢性疾病之一，尚無功能性治癒方法。所有類型的糖尿病都會在不同的身體部位引起各種併發症，增加整體死亡風險。根據國際糖尿病聯盟的數據，北美糖尿病病例數預計將從2017 年的4,600 萬增加到2045 年的6,200 萬人此外，2017 年有4.25 億人患有糖尿病，預計到2045 年這一數字將達到6.29 億人。。根據全球癌症觀察站 (GLOBOCAN) 2020 年發布的估計，全球報告了 1,930 萬癌症病例。美國、中國和印度的病例數明顯較高。同樣，根據世界衛生組織 2022 年 2 月發布的資料，全球約有 1,000 萬人因癌症死亡。癌症發生率的激增表明需要創新的癌症治療方法。單株抗體是一類有前景的標靶抗癌藥物，可增強免疫系統抑制癌細胞活性和消除癌細胞的天然能力。抗體藥物偶聯物（ADC）在癌症治療中也顯示出有希望的結果。專家、患者、初級保健臨床醫生和其他醫療保健專業人員對生物相似藥高效和安全的認知正在推動其需求。生物相似藥已被證明可以改善數百萬患者的生活品質。它們是治療許多疾病的有效且經濟高效的選擇，包括慢性皮膚病（如牛皮癬和異位性皮膚炎）、腸道疾病（如克隆氏症、腸躁症和結腸炎）、糖尿病、自身免疫性疾病、癌症、腎臟病條件和關節炎。生物相似藥開發商正在採用先進的生物加工技術來降低製造成本，這是決定最終消費價格的重要因素。幾乎所有生物相似藥開發商都在使用現代、尖端的生物加工技術。因此，隨著慢性病的日益流行，對治療危及生命的疾病的生物相似藥的需求不斷增加，從而推動了對生物加工的需求。

北美生物加工市場概況

遺傳和細胞疾病發病率的不斷上升導致對細胞療法的需求不斷增加。藥物研究和製造商協會(PhRMA) 關於細胞和基因治療管道的報告（於2020 年發布）顯示，目前有400 種細胞和基因療法正在開發中，用於治療從癌症到遺傳性疾病等多種疾病和病症。 2023 年 4 月，Cytiva 推出了 X 平台生物反應器，以一次性產品簡化上游生物加工作業。最初，這些生物反應器的尺寸為 50 L 和 200 L。

生物製藥產業的成長主要得益於技術進步、靈活性提高和營運成本低廉，也有利於美國的生物加工市場。根據國際貿易管理局（ITA）的數據，美國是最大的生物製藥市場和全球研發領導者。根據PhRMA統計，美國企業佔全球生物製藥研發工作的近50%，並成功開發出許多擁有智慧財產權的新藥。因此，美國生物製藥和生物技術公司為改善臨床試驗結果和確保病患安全而增加的研發投資，以及美國政府不斷增加的投資對精準醫療的吸引力日益增強，都有助於美國生物加工市場的成長。

北美生物加工市場收入及 2031 年預測（百萬美元）

北美生物加工市場細分

北美生物加工市場按產品、經營規模、製程、應用、最終用戶和國家分類。

根據產品，北美生物加工市場分為儀器和消耗品及配件。到2023年，儀器儀表領域將佔據更大的市場佔有率。此外，生物反應器細分分為中試規模、全規模和實驗室規模。此外，子分段層析系統又分為液相層析、氣相層析等。此外，消耗品和配件細分為試劑、細胞培養基、層析樹脂等。

從營運規模來看，北美生物加工市場分為商業營運和臨床營運。 2023年，商業營運領域佔據更大的市場佔有率。

依製程分類，北美生物製程市場分為下游生物製程和上游生物製程。到2023年，下游生物製程領域將佔據更大的市場佔有率。

根據應用，北美生物加工市場分為單株抗體、疫苗、重組蛋白、細胞和基因治療等。 2023 年，單株抗體細分市場佔最大市場。

就最終用戶而言，北美生物加工市場分為生物製藥公司、合約製造組織等。 2023 年，生物製藥公司細分市場佔最大市場。

按國家/地區分類，北美生物加工市場分為美國、加拿大和墨西哥。 2023 年，美國在北美生物加工市場佔有率中佔據主導地位。

Getinge AB、Thermo Fisher Scientific Inc、Sartorius AG、Corning Inc、Bio-Rad Laboratories Inc、Merck KGaA、3M Co、Eppendorf SE、Repligen Corp、Entegris Inc、Agilent Technologies Inc 和 Cytiva US LLC。是北美生物加工市場上的一些領先公司。

The sedentary life of older people has boosted the prevalence of lifestyle disorders, such as obesity and diabetes. Inherited genes can also express these conditions along with other health concerns such as cardiovascular disease (CVDs), Alzheimer's disease, and depression. As per the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime. According to the Centers for Disease Control and Prevention (CDC), approximately 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people had two or more chronic conditions in 2020. According to WHO, in 2020, there were more adults over 60 than children under five. The percentage of the global population over 60 will almost double from 12% to 22% between 2015 and 2050. Numerous chronic disorders, such as dementia, osteoarthritis, cancer, stroke, and cardiovascular disease, are known to be associated with aging. CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction caused because of hectic lifestyles, are among the significant causes of mortality across the world. As per the World Heart Foundation, mortality caused due to CVD has surged by 60% over the past 30 years (1990-2020). 20.5 million deaths were recorded in 2021 due to CVDs. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can cause various complications in different body parts, thereby increasing the overall risk of death. According to the International Diabetes Federation, the number of diabetic cases in North America is anticipated to grow from 46 million in 2017 to 62 million by 2045. Additionally, 425 million people had diabetes in 2017, and the number is anticipated to reach 629 million by 2045 worldwide, which is an increase of about 35%. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, 19.3 million cancer cases were reported across the world. The number of cases was significantly high in the US, China, and India. Similarly, as per the World Health Organization data published in February 2022, ~10 million people across the world have succumbed to death due to cancer. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody-drug conjugates (ADCs) have also shown promising results in cancer treatment. The recognition of biosimilars as efficient and safe by specialists, patients, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have been proven to improve the quality of life for millions of patients. They are impactful and cost-effective options for treating many diseases, including chronic skin conditions (such as psoriasis and atopic dermatitis), bowel diseases (such as Crohn's disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, which is an important factor in determining the final consumer prices. Nearly all biosimilar developers are using modern, cutting-edge bioprocessing techniques. Therefore, with the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing.

North America Bioprocessing Market Overview

Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. The Pharmaceutical Research and Manufacturers Association (PhRMA)'s report on the cell & gene therapy pipeline (published in 2020), revealed that there are 400 cell and gene therapies in development for targeting a variety of diseases and conditions from cancer to genetic disorders to neurologic conditions in the US. In April 2023, Cytiva launched X-platform bioreactors to simplify upstream bioprocessing operations with single-use products. Initially, these bioreactors were available in the sizes of 50 L and 200 L. The X-Platform bioreactors are now equipped with Figurate automation solution software, and they can increase process efficiency through ergonomic improvements, production capacity, and simplified supply chain operations.

The growth of the biopharmaceutical sector, mainly due to technological advancements, increasing flexibility, and low operational costs, also benefits the bioprocessing market in the US. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals and the global leader in R&D. According to the PhRMA, companies in the US account for nearly 50% of the global biopharmaceutical R&D work, and they have succeeded in developing many novel medicines for which they hold intellectual property rights. Thus, the increasing R&D investments by US-based biopharmaceutical and biotechnology companies to improve outcomes of clinical trials and ensure patient safety, and the growing traction toward precision medicine with rising investments by the US government contribute to the growth of the bioprocessing market in the US.

North America Bioprocessing Market Revenue and Forecast to 2031 (US$ Million)

North America Bioprocessing Market Segmentation

The North America bioprocessing market is categorized into product, scale of operation, process, application, end user, and country.

Based on product, the North America bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held a larger market share in 2023. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the sub segment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.

In terms of scale of operation, the North America bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held a larger market share in 2023.

By process, the North America bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment held a larger market share in 2023.

Based on application, the North America bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of end user, the North America bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies segment held the largest market share in 2023.

By country, the North America bioprocessing market is segmented into the US, Canada, and Mexico. The US dominated the North America bioprocessing market share in 2023.

Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC. are some of the leading companies operating in the North America bioprocessing market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Bioprocessing Market Landscape

4.1 Ecosystem Analysis
- 4.1.1 List of Vendors in the Value Chain

5. North America Bioprocessing Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Growing Biopharmaceutical Industry
5.2 Market Restraints
- 5.2.1 Stringent Regulatory Policies and Limitations Associated with Bioprocessing
5.3 Market Opportunities
- 5.3.1 Proliferating Demand for Personalized Medicine
5.4 Future Trends
- 5.4.1 Shift Toward Automated Cell Therapy Manufacturing
5.5 Impact of Drivers and Restraints:

6. Bioprocessing Market - North America Analysis

6.1 Bioprocessing Market Revenue (US$ Million), 2021-2031

7. North America Bioprocessing Market Analysis - by Product

7.1 Overview
7.2 Instruments
- 7.2.1 Overview
- 7.2.2 Instruments: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.2.2.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Instruments
    - 7.2.2.1.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Bioreactors
    - 7.2.2.1.2 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Chromatography Systems
7.3 Consumables & Accessories
- 7.3.1 Overview
- 7.3.2 Consumables & Accessories: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Consumables & Accessories

8. North America Bioprocessing Market Analysis - by Scale of Operation

8.1 Overview
8.2 Commercial Operations
- 8.2.1 Overview
- 8.2.2 Commercial Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Clinical Operations
- 8.3.1 Overview
- 8.3.2 Clinical Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Bioprocessing Market Analysis - by Process

9.1 Overview
9.2 Downstream Bioprocess
- 9.2.1 Overview
- 9.2.2 Downstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Upstream Bioprocess
- 9.3.1 Overview
- 9.3.2 Upstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Bioprocessing Market Analysis - by Application

10.1 Overview
10.2 Monoclonal Antibodies
- 10.2.1 Overview
- 10.2.2 Monoclonal Antibodies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Vaccines
- 10.3.1 Overview
- 10.3.2 Vaccines: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Recombinant Protein
- 10.4.1 Overview
- 10.4.2 Recombinant Protein: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.5 Cell & Gene Therapy
- 10.5.1 Overview
- 10.5.2 Cell & Gene Therapy: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
10.6 Others
- 10.6.1 Overview
- 10.6.2 Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Bioprocessing Market Analysis - by End User

11.1 Overview
11.2 Biopharmaceutical Companies
- 11.2.1 Overview
- 11.2.2 Biopharmaceutical Companies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Contract Manufacturing Organization
- 11.3.1 Overview
- 11.3.2 Contract Manufacturing Organization: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)

12. North America Bioprocessing Market - Country Analysis

12.1 North America: Bioprocessing Market Overview
- 12.1.1 North America: Bioprocessing Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 United States: Bioprocessing Market- Revenue and Forecast to 2031 (US$ Million)
  - 12.1.1.2 Overview
  - 12.1.1.3 United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.3.1 United States: Bioprocessing Market Breakdown, by Product
    - 12.1.1.3.1.1 United States: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.3.1.1.1 United States: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.3.1.1.2 United States: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.3.1.2 United States: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.3.2 United States: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.3.3 United States: Bioprocessing Market Breakdown, by Process
    - 12.1.1.3.4 United States: Bioprocessing Market Breakdown, by Application
    - 12.1.1.3.5 United States: Bioprocessing Market Breakdown, by End User
  - 12.1.1.4 Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.4.1 Overview
  - 12.1.1.5 Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.5.1 Canada: Bioprocessing Market Breakdown, by Product
    - 12.1.1.5.1.1 Canada: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.5.1.1.1 Canada: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.5.1.1.2 Canada: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.5.1.2 Canada: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.5.2 Canada: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.5.3 Canada: Bioprocessing Market Breakdown, by Process
    - 12.1.1.5.4 Canada: Bioprocessing Market Breakdown, by Application
    - 12.1.1.5.5 Canada: Bioprocessing Market Breakdown, by End User
  - 12.1.1.6 Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.6.1 Overview
  - 12.1.1.7 Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
    - 12.1.1.7.1 Mexico: Bioprocessing Market Breakdown, by Product
    - 12.1.1.7.1.1 Mexico: Bioprocessing Market Breakdown, by Instruments
    - 12.1.1.7.1.1.1 Mexico: Bioprocessing Market Breakdown, by Bioreactors
    - 12.1.1.7.1.1.2 Mexico: Bioprocessing Market Breakdown, by Chromatography Systems
    - 12.1.1.7.1.2 Mexico: Bioprocessing Market Breakdown, by Consumables & Accessories
    - 12.1.1.7.2 Mexico: Bioprocessing Market Breakdown, by Scale of Operation
    - 12.1.1.7.3 Mexico: Bioprocessing Market Breakdown, by Process
    - 12.1.1.7.4 Mexico: Bioprocessing Market Breakdown, by Application
    - 12.1.1.7.5 Mexico: Bioprocessing Market Breakdown, by End User

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in the Bioprocessing Market
13.3 Inorganic Growth Strategies
- 13.3.1 Overview
13.4 Organic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Getinge AB
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Thermo Fisher Scientific Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sartorius AG
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Corning Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Bio-Rad Laboratories Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Merck KGaA
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 3M Co
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Eppendorf SE
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Repligen Corp
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Entegris Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Agilent Technologies Inc
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments
14.12 Cytiva US LLC
- 14.12.1 Key Facts
- 14.12.2 Business Description
- 14.12.3 Products and Services
- 14.12.4 Financial Overview
- 14.12.5 SWOT Analysis
- 14.12.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Bioprocessing Market Segmentation
Table 2. List of Vendors
Table 3. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Instruments
Table 4. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Bioreactors
Table 5. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Chromatography Systems
Table 6. Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - By Consumables & Accessories
Table 7. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 8. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 9. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 10. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 11. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 12. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 13. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 14. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 15. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 16. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 17. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 18. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 19. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 20. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 21. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 22. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 23. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 24. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 25. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Product
Table 26. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Instruments
Table 27. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Bioreactors
Table 28. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Chromatography Systems
Table 29. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Consumables & Accessories
Table 30. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Scale of Operation
Table 31. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Process
Table 32. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by Application
Table 33. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 34. Recent Inorganic Growth Strategies in the Bioprocessing Market
Table 35. Recent Organic Growth Strategies in the Bioprocessing Market
Table 36. Glossary of Terms, Bioprocessing Market

List Of Figures

Figure 1. North America Bioprocessing Market Segmentation, by Country
Figure 2. Bioprocessing Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Bioprocessing Market Revenue (US$ Million), 2021-2031
Figure 5. Bioprocessing Market Share (%) - by Product (2023 and 2031)
Figure 6. Instruments: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Consumables & Accessories: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Bioprocessing Market Share (%) - by Scale of Operation (2023 and 2031)
Figure 9. Commercial Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Clinical Operations: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Bioprocessing Market Share (%) - by Process (2023 and 2031)
Figure 12. Downstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Upstream Bioprocess: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Bioprocessing Market Share (%) - by Application (2023 and 2031)
Figure 15. Monoclonal Antibodies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Vaccines: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Recombinant Protein: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Cell & Gene Therapy: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Bioprocessing Market Share (%) - by End User (2023 and 2031)
Figure 21. Biopharmaceutical Companies: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Contract Manufacturing Organization: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. North America: Bioprocessing Market, by Key Country - Revenue (2023) (US$ Million)
Figure 25. North America: Bioprocessing Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 26. United States: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Canada: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Mexico: Bioprocessing Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. Growth Strategies in the Bioprocessing Market